Adherence to medications for cholesterol, hypertension, and diabetes helped Medicare beneficiaries avoid up to $29.2 billion in healthcare costs over six years (2016-21), according to the 2024 National Impact Assessment of CMS Quality Measures Report. This report underscores the importance of high-impact measures for chronic conditions, as evidence-based management efforts can significantly reduce complications and mortality.
PQA has issued an eight-point call to action for improving the quality and measurement of medication therapy management (MTM) services. The call was developed with extensive stakeholder input as part of a national, multi-phase initiative that PQA launched in 2023 to identify a pathway for new quality measures. It is the focus of a report published this month, “Advancing Medication Therapy Management Quality Measurement.”.
PQA has received a 2024 Power of Associations Gold Award from the American Society of Association Executives (ASAE) for the PQA Diverse Quality Leaders Program. The program helps individuals at various career stages become leaders in health care quality focused on safe, effective and appropriate medication use.
PQA provides healthcare quality experience to students from a wide variety of disciplines. This summer, we are hosting four students through our internship and MPH practicum programs.
Registration is open for the 2024 PQA Leadership Summit, November 7-8, 2024, in Arlington, Va., and PQA Convenes: Quality Medication Use in Rare Disease, which will take place before the summit on November 7. This year’s summit will focus on pharmacy measure use in value-based arrangements (VBAs) and quality improvement programs.
PQA published the Strategies to Expand Value-Based Pharmacist-Provided Care Action Guide five years ago. The guide was designed to spark conversation and foster collaboration between community pharmacy organizations, pharmacists and health care payers.
Through convening events, research, pilots and work to develop standard pharmacy quality measures, PQA has been a national leader in advancing pharmacist-provided care. A 2018 PQA-convened task force identified 15 strategies to expand value-based pharmacist-provided care, which form the centerpiece of the 2019 Strategies to Expand Value-Based Pharmacist-Provided Care Action Guide. The guide was designed to spark conversation and foster collaboration between community pharmacy organizations, pharmacists and health care payers.
Patients receiving specialty medications often have complex, high-cost treatment needs, necessitating close management from care teams, including specialty pharmacies. Recognizing this, specialty pharmacy stakeholders have articulated the need for standardized turnaround time (TAT) measurement and reporting to better understand a key aspect of specialty pharmacy quality.
The use of specialty medicine has grown rapidly in recent decades, fueling parallel growth in the number of specialty pharmacies that serve patients who are prescribed specialty medications. Patients receiving specialty medications often have complex, high-cost treatment needs, necessitating close management from care teams, including specialty pharmacies. Specialty pharmacies dispense medications, for which timely initiation of therapy is a clinical priority to optimize outcomes.
Diverse Voices in Quality is a PQA blog series that showcases the successful career paths and experiences of medication use quality professionals from diverse groups at PQA member organizations. A part of PQA’s Diverse Quality Leaders Program, this series celebrates the achievements of our members who reflect our nation’s diversity and provides everyone with insights and inspiration for becoming a leader in quality.
PQA, in partnership with Inovalon, is evaluating the impact of the Medicare out-of-pocket cost cap for insulin on persistence to basal insulin.
More than 400 leaders from PQA member organizations attended the 2024 PQA Annual Meeting, May 14-16, to network, engage and gain actionable insights.
Oral anticancer medications (OAMs) are a growing and important tool in the fight against cancer. More than 120 FDA-approved OAMs were used in clinical practice in 2022, and OAMs represent more than one-third of cancer medications in the development pipeline.
PQA members and health quality professionals gathered in Baltimore, Md., May 14-16, for the 2024 PQA Annual Meeting.
The 2024 PQA Annual Meeting poster session featured 23 quality improvement and research projects. Sponsored by Pharmacy Quality Solutions, the session provided an opportunity for authors to showcase their work and for attendees to engage in insightful dialogue about healthcare quality.
PQA will host an all-member webinar on Thursday, May 30, from 1:00-1:30 p.m. ET, to discuss one health plan performance measure that is being considered for retirement: Use of Opioids from Multiple Providers in Persons Without Cancer (OMP).
This guest blog is one in a series by sponsors of the 2024 PQA Annual Meeting on a survey which highlights opportunities for pharmacies and payers to boost medication compliance. PQA does not endorse, recommend or favor any product, service or organization that is a sponsor.
The 2024 PQA Annual Meeting is just 10 days away! The PQA Annual Meeting consistently brings together stakeholders from across healthcare focused on improving quality medication use. Connecting with old colleagues, and making new acquaintances, is consistently a top-rated benefit of the meeting. .
The PQA Postdoctoral Executive Fellowship helps produce the next generation of leaders in health care quality through a full-time, 12-month program. Executive Fellows collaborate with PQA staff, members and other stakeholders on a variety of initiatives to improve medication use quality. During the fellowship, individuals will expand their skills and experience in project management, quality measure design and implementation, non-profit administration and association management, and health care quality research.
Collaboration is one of PQA's greatest attributes, and our measure development process embodies how our diverse member organizations reach consensus on evaluating medication use quality. The public comment period is an important part of our systematic and transparent consensus-based process.
